Speakers

Expand/Collapse

Speaker TBC

Armata Pharmaceuticals

Day One

3:05 pm | A Review of Armata Pharmaceuticals Clinical Candidates

Carrie-Lynn Langlais Furr
Co-Founder & CEO
Bacteriophage & Drug Development Consultants

Carrie-Lynn Langlais Furr, PhD, RAC is Bacteriophage & Drug Development Consultants’ co‑founder and principle consultant, a CARB-X Scientific Advisor, and an Editor of PHAGE Therapy, Applications, and Research journal. Previously, she was Vice President of Regulatory Affairs & Program Management for AmpliPhi Biosciences (now Armata Pharmaceuticals), a public, clinical-stage phage therapy company, for nearly 3 years. Her 13 years of pharmaceutical product development experience, specializing in regulatory affairs, includes 10 years in the CRO industry. She obtained 7 FDA market approvals (1 biologic-device combination and 6 drugs), prepared and submitted several INDs enabling clinical trials to proceed, 2 international phage therapy Expanded Access programs, several formal Regulatory Authority interactions and negotiations (including phage therapies), obtained gene therapy Orphan Designation, and provided expert consultation to over 30 companies at various stages of development and for a broad range of indications. Dr. Furr’s publications cover peer-reviewed phage characterization and phage therapy clinical case studies. She holds a PhD in Biochemistry and Biophysics from Texas A&M University and studied under Professor Ryland Young to elucidate the antibiotic mechanism of A2, the multifunctional maturation protein of ssRNA bacteriophage Qbeta. Dr. Furr has held Regulatory Affairs Certification from the Regulatory Affairs Professionals Society since 2009.

Day Two

9:00 am | Panel Session: Priorities to Establish a Bacteriophage Sector

Mark Albrecht
Brand Chief – Anti-Bacterial Program
BARDA

Day Two

4:00 pm | Panel Discussion: How to Attract Private or Public Funding to You Research?

Sailaja Puttagunta
CMO
BiomX

Dr. Sailaja Puttagunta, M.D., was most recently Vice President, Development at Iterum Therapeutics, a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens. Prior to Iterum, Dr. Puttagunta served as VP, Medical Affairs for Anti-infectives at Allergan from early 2015 and was the VP of Development and Medical Affairs at Durata Therapeutics, Inc. prior to its acquisition by Actavis plc. From 2006 to 2012, Dr. Puttagunta led teams within clinical development and medical affairs on various antibiotic compounds at Pfizer Inc. Dr. Puttagunta has 20 years of clinical, academic and research experience in medicine and in the sub-specialty of infectious diseases. She graduated from Gandhi Medical College in Hyderabad, India and completed her residency in Internal Medicine and a fellowship in Infectious Diseases at Yale University School of Medicine. She also holds an MS in Biochemistry from the New York University School of Medicine.

Day Two

12:00 pm | Bacteriophage Therapy for IBD

Richard Alm
Alliance Director
CARB-X

Day Two

4:00 pm | Panel Discussion: How to Attract Private or Public Funding to You Research?

Steven Theriault
CEO & CSO
Cytophage Technologies

Dr. Steven Theriault is a synthetic biologist with 20 years research and entrepreneurial experience in generating biological solutions for biological problems.  Early in his career, he was a member of the team that created the reverse genetic systems critical to the development of the Canadian Ebola vaccine as well as many novel and innovative diagnostic tools to aid in the fight against Ebola.  As Chief of the Applied Research Program at the Canadian Science Centre for Human and Animal Health, Dr. Theriault worked extensively at the global level on issues related to the efficacy of microbicides in outbreak zones and containment laboratories. Recently, Dr. Theriault research interests have turned to combating antimicrobial resistance with synthetic bacteriophages. Dr. Theriault’s company, Cytophage Technologies Inc., unlocks the potential of nature’s elegant and harmless antibacterial solution – phages.  Cytophage’s template technology replaces the lengthy discover-in-nature process and bacterial resistance common to natural phages with tailor-made, highly effective, synthetic phages.  Cytophage has been recognised internationally as an innovative and potentially disruptive technology. Dr. Theriault’s goal is to enable phages to become mainstream in treating human and animal bacteria-related infections and contaminations, thereby reducing needless suffering and averting the WHO-predicted crisis from antibiotic resistant infections.

Pre-Conference Focus Day

10:40 am | Using Bacteriophages to Prevent Disease in a Large Scale Agricultural Setting

Xavier Duportet
Co-Founder & CEO
Eligo Bioscience

Dr. Duportet is a genome architect and science entrepreneur. He cofounded Eligo Bioscience in 2014 during the last year of his Ph.D. in synthetic biology, a joint program between the Massachusetts Institute of Technology (MIT) and the French research institute Inria. He has raised $26 million since then from international investors to develop a new generation of ultraprecise biotherapeutics based on the delivery of CRISPR/Cas gene-editing systems to the microbiome. Eligo was recently selected as a Technology Pioneer by the World Economic Forum (WEF), while Dr. Duportet has won a number of international awards and recognitions, including French Innovator of the Year from the MIT Technology Review (MIT TR), the MIT TR35 award, the Forbes 30 Under 30 list, Young Global Leader from the WEF, and France Biotech’s Rising Star award. He is also the founder and president of Hello Tomorrow, a global nonprofit that identifies and supports promising early-stage entrepreneurs who are transforming disruptive scientific technologies into products or services to solve societal and industrial challenges. Since 2014, the 25 finalists of its yearly startup competition have already raised more than €350 million. Dr. Duportet also launched Deeptech Founders in 2019, a European-wide training program for entrepreneur–scientists to help them to refine their spinoff startup concepts. In less than a year, 10 startups have already been created and have raised more than €12 million.

Day Two

12:20 pm | Using Phages for Gene Therapy of the Microbiome

Matthew Dunne
Senior Researcher
ETH Zurich, Institute of Food, Nutrition and Health

Day Two

2:20 pm | Reprogramming Phage Host Ranges Through Genetic Engineering

Cara Fiore
Microbiologist
FDA, Office of Vaccines Research & Review

Day One

9:10 am | Regulatory Considerations for Bacteriophage Therapy

Jonathan Kotula
Head of Science
Felix Biotechnology

Day Two

10:50 am | Predicting Phage-Host Interactions

Amit Vikram
Senior Research Scientist
Intralytix

Pre-Conference Focus Day

1:00 pm | Phages for Enhanced Food Safety - An Industry Perspective

Michael Koeris
Professor, Bioprocessing, Adjunt/Keck Gradute
Amgen Bioprocessing Center/Claremont Colleges

Day One

9:00 am | Chairperson’s Opening Remarks & Review of Field

Andrew Millard
Professor
Leicester University

Day Two

2:00 pm | Engineering of Coliphages

Tuval Ben-Yehezkel
CEO
Loop Genomics

Day One

11:00 am | Single-Molecule Long-Read Sequencing of Phage Mutational Landscape

Danish Malik
Senior Lecturer
Loughborough University

Danish Malik’s research focus is on the application of Chemical Engineering Science principles to address the global health challenge of antibiotic resistance. His research group is working on the development of scalable manufacturing platforms for next-generation antibiotic biotherapeutics including bacteriophages, bacteriocins, endolysins and virus like particles (VLPs), their production and purification, micro- and nanoencapsulation and targeted delivery to treat bacterial infections including intracellular infections across a range of clinical areas.

Day One

11:35 am | Using Advanced Metrology Tools to Evaluate Phage Aggregation in Liquid Formulations

Yu-Wei Wayne Lin
Pharmacometrician
Monash University

Day One

4:15 pm | Model-Informed Drug Discovery & Development for Bacteriophage Therapy: A Focus on Preclinical Pharmacokinetics & Pharmacodynamics

Jorge Bardales
Co-Founder & CSO
Nextbiotics

Pre-Conference Focus Day

10:00 am | Enhancing Phage Capacities Through A Directed Evolution Platform

Joseph Campbell
Program Officer
NIH

Day Two

4:00 pm | Panel Discussion: How to Attract Private or Public Funding to You Research?

Mark Fitzgerald
IP Counselling
Nixon Peabody

Day Two

3:30 pm | Patent Protection for Bacteriophage Therapeutics: Issues & Approaches

Saima Aslam
Associate Professor, Division of Infectious Diseases and Global Public Health
iPATH - Center for Innovative Phage Applications and Therapeutics

Day One

2:00 pm | Clinical Design Mastermind Session

Minmin Yen
CEO
Phage Pro

Day One

11:15 am | Democratizing Phage Therapy: Using Phage Therapy to Intervene in Cholera Epidemics

Jean-Paul Pirnay
Laboratory Manager/Senior Scientist
Queen Astrid Military Hospital

Day One

9:30 am | Bringing Phages from the Environment to the Patient: The Experience of the Brussels Military Hospital

Pingfeng Yu
Research Scientist
Rice University

Day One

4:35 pm | Hitchhiking Behavior in Bacteriophages: Implications for Phage Therapy and Biofilm Engineering

Angela Moreno
CEO
SciPhage

Pre-Conference Focus Day

10:20 am | Exploring Phage-Therapy In the Poultry Industry

Olivia McAullife
Principal Scientist
Teagasc Food Research Centre

Pre-Conference Focus Day

1:20 pm | Application of Phages in the Food Sector: The Future for Control & Detection of Pathogens?

Clara Leandro
Head, Infection
Technophage

Day One

2:45 pm | Going Into REVERSE: Assessing the Safety of Bacteriophage Treatment in the Management of Diabetic Foot Infections

Chris Lis
CTO
Uniphage

Pre-Conference Focus Day

1:40 pm | Systems Learning Approach to Developing Bacteriophage for Usage in Crop Protection

Sofia Sigal-Passeck
CEO
Uniphage

Pre-Conference Focus Day

1:40 pm | Systems Learning Approach to Developing Bacteriophage for Usage in Crop Protection

Panos Kalatzis
Postdoctoral Scholar/Co-Founder
University of Copenhagan/Aquatic Biologicals

Pre-Conference Focus Day

11:00 am | Going Viral Against Bacteria: Implications of Using Phage Therapy in Aquaculture

Srivatsan Raman
Assistant Professor
University of Wisconsin-Madison

Day Two

2:40 pm | High-Throughput Targeted Genome Engineering to Build Synthetic Therapeutic Bacteriophages

Bryan Hsu
Assistant Professor
Virginia Tech

Day One

11:55 am | An Aqueous Based Encapsulation for Oral Delivery

Damon Ellison
Chief, Bacteriohage Therapeutics
Walter Reed Army Institute of Research

Day Two

10:30 am | Development of Fixed Phage Cocktails in the Fight Against Multidrug-Resistant Organisms